{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Castro J"],"funding":["Generalitat de Catalunya, DGU","Universitat de Girona","Ministerio de Economia y Competitividad (MINECO) Spain"],"pagination":["2801"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9781652"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(12)"],"pubmed_abstract":["A family of dinuclear iron (II) compounds with iminopyridine-based ligands displays selective cytotoxic activity against cancer cell lines. All compounds have IC<sub>50</sub> values 2-6 fold lower than that of cisplatin, and 30-90 fold lower than that of carboplatin for the tumor cell lines assayed. Comparing the IC<sub>50</sub> values between tumor and non-tumor cell lines, the selectivity indexes range from 3.2 to 34, compound <b>10, [Fe<sub>2</sub>(4)<sub>2</sub>(CH<sub>3</sub>CN)<sub>4</sub>](BF<sub>4</sub>)<sub>4</sub></b>, showing the highest selectivity. Those compounds carrying substituents on the iminopyridine ring show the same cytotoxicity as those without substituents. However, the electronic effects of the substituents on position 6 may be important for the cytotoxicity of the"],"journal":["Pharmaceutics"],"pubmed_title":["Dinuclear Iron Complexes of Iminopyridine-Based Ligands as Selective Cytotoxins for Tumor Cells and Inhibitors of Cancer Cell Migration."],"pmcid":["PMC9781652"],"funding_grant_id":["BIO2013-43517","SGR2014-70 and 2017 SGR 1720","MPCUdG2016-18 and MPCUdG2016/048"],"pubmed_authors":["Marsal A","Vilanova M","Alonso-De Gennaro MJ","Romero I","Castro J","Bravo M","Claver C","Benito A","Martinez-Ferrate O","Alberti M","van Leeuwen PWNM"],"additional_accession":[]},"is_claimable":false,"name":"Dinuclear Iron Complexes of Iminopyridine-Based Ligands as Selective Cytotoxins for Tumor Cells and Inhibitors of Cancer Cell Migration.","description":"A family of dinuclear iron (II) compounds with iminopyridine-based ligands displays selective cytotoxic activity against cancer cell lines. All compounds have IC<sub>50</sub> values 2-6 fold lower than that of cisplatin, and 30-90 fold lower than that of carboplatin for the tumor cell lines assayed. Comparing the IC<sub>50</sub> values between tumor and non-tumor cell lines, the selectivity indexes range from 3.2 to 34, compound <b>10, [Fe<sub>2</sub>(4)<sub>2</sub>(CH<sub>3</sub>CN)<sub>4</sub>](BF<sub>4</sub>)<sub>4</sub></b>, showing the highest selectivity. Those compounds carrying substituents on the iminopyridine ring show the same cytotoxicity as those without substituents. However, the electronic effects of the substituents on position 6 may be important for the cytotoxicity of the","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-22T13:18:26.938Z","creation":"2025-04-06T00:38:09.742Z"},"accession":"S-EPMC9781652","cross_references":{"pubmed":["36559294"],"doi":["10.3390/pharmaceutics14122801"]}}